Long R3 IGF-1 Analog · Direct IGF-1 Receptor Agonist · Protocol Guide
IGF-LR3: The Honest Muscle Growth Peptide Guide
IGF-LR3 (Long R3 IGF-1) is a modified, longer-acting version of insulin-like growth factor 1 built to dodge the binding proteins that normally restrain IGF-1. It is potent and it is a research molecule: there are no human muscle-building trials, the bodybuilding use is off-label and unstudied in healthy adults, and the same growth signal that grows muscle also carries hypoglycemia and cancer-signaling concerns. This guide draws those lines.
- FDA Status
- Investigational, 503A Compounded
- Pharmacy
- Optimal Balance Pharmacy (503A licensed)
- Medical Service
- RxPepsDirect, physician-supervised
- Access
- 28 U.S. States
Our promise: There are no human clinical trials of IGF-LR3 for muscle growth. The bodybuilding protocol is built on cell and animal data plus user reports, not on tested medicine in healthy adults. We say that plainly, and we flag the hypoglycemia risk, the cancer-signaling concern, and the WADA prohibition rather than burying them.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed June 8, 2026.On this page
Section 01
What IGF-LR3 Actually Is
IGF-LR3, fully named Long R3 insulin-like growth factor 1, is a modified version of the natural hormone IGF-1. Two changes were engineered into it. An arginine replaces the glutamic acid at position 3, and a 13-amino-acid extension is added to one end. The point of both edits is the same: to make the molecule far less likely to be grabbed by the IGF binding proteins that normally escort and restrain IGF-1 in the bloodstream. Free of that leash, IGF-LR3 stays active longer and reaches receptors more readily than native IGF-1.
It is worth being precise about where this molecule came from. Long R3 IGF-1 was not developed as a medicine. It was created as a research and manufacturing reagent, a potent IGF-1 analog used to drive cell proliferation in laboratory culture and bioreactors. The recent literature describes producing it for exactly that purpose, confirming its bioactivity against standard IGF-1 in cell-growth assays. The bodybuilding use is a repurposing of a lab tool, not a therapy that went through clinical development.
What IGF-LR3 is not is just as important. It is not a tested human muscle drug. It is not a growth hormone secretagogue like sermorelin or ibutamoren that nudges your own pituitary; it is the downstream growth signal itself, delivered directly. And it is not a benign molecule you can dose casually. The same property that makes it potent, its escape from binding-protein regulation, is the property that makes its blood-sugar and growth-signaling effects harder to contain.
R3
Arginine swap at position 3, plus a 13-residue N-terminal extension
0
Controlled human trials of IGF-LR3 for muscle growth in healthy adults
S2
World Anti-Doping Agency prohibited-list class for IGF-1 and its analogues
503A
Pathway for U.S. compounded access under physician prescription
Section 02
Who It Is Actually For
The honest answer is narrower than the marketing. IGF-LR3 has no approved human indication. The profiles below describe who tends to seek it and how well the evidence actually supports that use. In almost every case the basis is mechanistic inference, not tested outcomes.
| Profile | Primary Motivation | Evidence Basis | Fit |
|---|---|---|---|
| Advanced Physique Athlete (Off-Label) | Direct muscle cell growth, lean tissue development | IGF-1 muscle biology plus animal and cell data. No human muscle trial of IGF-LR3. | Off-Label, Unstudied |
| Recovery-Phase Trainee | Support tissue repair and growth during rebuilding | Plausible from IGF-1 repair signaling, never trialed for this use in humans. | Exploratory |
| General Anti-Aging / Biohacking | Growth signaling for vitality goals | Extrapolated. Higher IGF-1 is also linked to higher cancer risk in cohort data. | Speculative, Risk-Weighted |
| Diabetic or Pre-Diabetic | Any goal | Hypoglycemia risk and glucose dysregulation make this molecule a poor fit. | Not Appropriate |
| Athlete Subject to Anti-Doping Testing | Recovery or growth during training | IGF-1 analogues are prohibited under WADA S2 at all times. | Banned, Do Not Use |
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Profile
Primary Motivation
Evidence Basis
Fit
Section 03
How IGF-LR3 Works
IGF-LR3 binds the IGF-1 receptor on cell surfaces and switches on the same growth pathways that native IGF-1 uses, principally the PI3K and ERK cascades. Those pathways drive cell survival, protein synthesis, and cell division. The engineered changes do not give it a new mechanism; they make the old mechanism run longer and harder by keeping the molecule free of its carrier proteins.
Direct IGF-1 Receptor Activation
Unlike GH secretagogues that work upstream at the pituitary, IGF-LR3 is the growth signal itself. It binds IGF-1 receptors directly on muscle and other tissue, bypassing the body's normal regulation of how much IGF-1 is released.
PI3K and ERK Signaling
In cell studies, IGF-1 acting through its receptor requires both the PI3K and ERK pathways to drive proliferation. These are the same growth and survival cascades that underlie its effects on tissue, which is also why the signal is not muscle-specific.
Hyperplasia vs Hypertrophy
Bodybuilding lore frames IGF-LR3 as a driver of hyperplasia, new muscle cell formation. In a controlled animal study, an IGF-1 analog drove cell division (hyperplasia) but did not by itself drive cell enlargement (hypertrophy). The proliferation claim has more support than the size claim.
Insulin-Like Glucose Effect
IGF-1 overlaps with insulin signaling and can lower blood glucose. Because IGF-LR3 stays free and active longer than native IGF-1, that glucose-lowering effect is harder to contain, which is the root of the hypoglycemia risk.
Section 04
What the Evidence Shows
This section matters more than usual for IGF-LR3, because the gap between the confident online protocols and the actual record is wide. Here is the actual evidence base, and what it does and does not support.
| Study | Design | Key Finding | Strength |
|---|---|---|---|
| Lu 2023 (Appl Microbiol Biotechnol) [1] | Recombinant production, cell-proliferation assays | LR3 IGF-1 was produced and confirmed bioactive, matching or exceeding standard IGF-1 at driving cell growth in culture. | Reagent Characterization |
| Sundgren 2003 (Am J Physiol) [2] | Animal and cell, fetal sheep cardiomyocytes | LR3 IGF-1 drove cell proliferation (hyperplasia) via PI3K and ERK but did not by itself cause cell enlargement (hypertrophy). | Mechanistic, Preclinical |
| Levolger 2019 (Sci Rep) [3] | Animal cancer-cachexia model | LR3 IGF-1 limited muscle loss, but at the expense of accelerated tumor growth in the tumor-bearing animals. | Safety Signal, Animal |
| Engel 2024 (J Alzheimers Dis) [4] | Animal, intranasal LR3 in Alzheimer model mice | Improved body composition but failed to preserve cognition. The authors did not support LR3 as a monotherapy. | Off-Target, Animal |
| Mukama 2023 (JCEM) [5] | Human cohort, EPIC-Heidelberg, IGF-1 levels | Higher circulating IGF-1 was linked to higher breast and prostate cancer risk. Context for the growth-signal concern. | Human, IGF-1 Context |
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Study
Design
Key Finding
Strength
Section 05
Realistic Expectations
Because there is no human trial, any timeline is reconstructed from IGF-1 biology and user reports rather than measured endpoints. Treat the windows below as rough expectations, not promises, and read them alongside the safety section.
Glucose Sensitivity Shows First
The earliest noticeable effect is often not muscle but blood sugar. Lightheadedness, hunger, or shakiness after a dose are signs of the insulin-like glucose drop and are the reason dosing alongside food and provider guidance matters from day one.
Local Pump and Fullness
Users commonly report a localized fullness or pump in trained muscle. This is a subjective, short-term observation, not a measured gain in lean mass, and it should not be read as proof the protocol is working.
Claimed Growth Window
This is where online protocols claim cellular growth begins. The cell and animal data make proliferation plausible, but no human trial has measured how much, if any, lean mass this produces in a healthy adult.
Cycle End and Reassessment
Typical user cycles run four to six weeks, partly out of caution about prolonged growth-signal exposure. This is the point to stop, reassess with your prescriber, and check how your glucose handling has behaved across the cycle.
Section 06
Dosing Protocol
There is no trial-validated human dose for IGF-LR3, so the figures below reflect cautious clinical practice and common user protocols, not established medicine. Your RxPepsDirect physician sets the starting dose, the ceiling, and the cycle length based on your history and glucose tolerance.
| Context | Dose | Route / Frequency | Evidence Basis |
|---|---|---|---|
| RxPepsDirect Standard Start | 20 mcg/day | Subcutaneous, daily, 4 to 6 week cycle | Clinical Practice, Conservative |
| Common User Range | 20 to 40 mcg/day | Subcutaneous, daily | Anecdotal, Not Trialed |
| Higher Doses | Above 40 mcg/day | Subcutaneous, daily | Rising Hypoglycemia Risk |
| Cycle Length | 4 to 6 weeks | Then a planned off period | Caution-Driven, Not Evidence-Driven |
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Context
Dose
Route / Frequency
Evidence Basis
Subcutaneous injection into abdominal fat with a standard insulin syringe. Most users dose alongside a meal or carbohydrate source to blunt the glucose drop, and avoid dosing before fasted activity or sleep without a plan for low blood sugar. Cycles are kept short by convention, reflecting unease about prolonged growth-signal exposure rather than any trial that defined a safe duration. Note that the entire dosing framework is built on inference: there is no human study that established a therapeutic window for this molecule.
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Section 08
Safety and Side Effects
IGF-LR3 carries real, mechanism-driven risks that set it apart from milder peptides. The two that matter most are hypoglycemia and the growth-signaling concern. Neither is hypothetical, and both are the reason this molecule belongs under physician supervision rather than in a self-directed cycle.
| Consideration | Detail | Action |
|---|---|---|
| Hypoglycemia | IGF-1 lowers blood glucose, and the binding-protein escape extends that effect | Dose with food, keep fast-acting carbohydrate on hand, never dose before fasted exercise or sleep without a plan. |
| Cancer / growth-signal risk | Higher IGF-1 is linked to higher cancer risk in human cohorts; an analog accelerated tumor growth in an animal model | Disclose any personal or family cancer history. With that history, do not use. |
| Glucose dysregulation in diabetics | Insulin-like activity complicates blood-sugar control | Not appropriate for diabetics or pre-diabetics without specialist management. |
| Pregnancy / lactation | No safety data, active growth signal | Avoid. |
| Anti-doping tested athletes | IGF-1 analogues prohibited under WADA S2 at all times | Do not use if you are subject to testing. |
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Consideration
Detail
Action
Section 09
Stacking
Commonly Paired With
CJC-1295 / Ipamorelin
A GH secretagogue stack works upstream at the pituitary while IGF-LR3 acts downstream. Users pair them to combine the natural pulse with a direct signal. Provider oversight is essential given the additive glucose effect.
BPC-157
Tissue repair through a separate pathway, often paired during recovery-focused cycles. Separate injection windows, no direct timing conflict.
Avoid or Use Caution
Insulin or other glucose-lowering agents
Stacking IGF-LR3 with insulin compounds the hypoglycemia risk dangerously. This combination is a known cause of severe low-blood-sugar events and should not be self-directed.
Use with active or prior cancer
A direct growth signal alongside any malignancy concern is the wrong combination. Avoid.
Pregnancy / lactation
No safety data. Avoid.
Section 10
Pricing
Pharmacy: Medication
$145 per 1 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted, FedEx overnight in a reusable cooled travel case.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including history review, glucose and cancer-risk screening, protocol design, prescription writing, and follow-up. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 28 States
503A Licensed Pharmacy
Optimal Balance Pharmacy, U.S. licensed
Physician Prescription Required
Compounded medication, Rx only
Investigational Compound
Preclinical evidence, no FDA approval
WADA Prohibited (S2)
Banned in tested sport at all times
IGF-LR3 is an investigational compound with no FDA approval for any indication. In the United States it is available through 503A patient-specific compounding under a physician prescription. The 503A pathway is the documented legal route for compounded peptide access, and RxPepsDirect prescribers serve patients in 28 states. Separately, and importantly for any competitor: IGF-1 and its analogues are prohibited at all times under section S2 of the World Anti-Doping Agency Prohibited List. Legal to be prescribed is not the same as legal to compete on.
Section 12
Community Q&A
Is there human evidence that IGF-LR3 builds muscle?
No. There are no controlled human trials of IGF-LR3 for muscle growth in healthy adults. The molecule was created as a lab and manufacturing reagent, and the muscle protocol online rests on cell-culture and animal data plus user reports. IGF-1 muscle biology is real, but the specific claim that injecting this analog builds lean mass in a healthy person has not been tested.
Why does IGF-LR3 cause low blood sugar?
IGF-1 overlaps with insulin signaling and lowers blood glucose. IGF-LR3 is engineered to evade the binding proteins that normally restrain IGF-1, so more of it stays free and active for longer. That extended activity is what raises the hypoglycemia risk. Dose with food, keep fast-acting carbohydrate nearby, and do not dose before fasted exercise or sleep without a plan.
Is it banned in sports?
Yes. IGF-1 and its analogues are prohibited at all times, in and out of competition, under section S2 of the World Anti-Doping Agency Prohibited List. IGF-LR3 is squarely inside that class. If you are subject to testing, treat it as banned.
Does the cancer concern apply to IGF-LR3?
It is a reasonable concern, not a settled fact for this exact molecule. Higher circulating IGF-1 is linked to higher risk of certain cancers in human cohorts, and an IGF-1 analog accelerated tumor growth in an animal cachexia model. None of that proves IGF-LR3 causes cancer in people, but it is why a cancer history is a reason not to use it.
How is this different from sermorelin or ibutamoren?
Sermorelin and ibutamoren are GH secretagogues. They nudge your own pituitary to release growth hormone, which your body still regulates. IGF-LR3 is the downstream growth signal delivered directly, bypassing that regulation. That makes it more potent and less self-limiting, which is exactly why its risk profile is higher.
Section 13
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your IGF-LR3 under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for the glucose and cancer-risk concerns specific to this molecule, designs your protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
This guide flags that there is no human muscle trial, that the hypoglycemia risk is real, that higher IGF-1 is linked to cancer risk in human data, and that the molecule is prohibited under WADA S2. We do not hide limitations to make a sale.
Legal Access in 28 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription, for patients in 28 U.S. states.
References
- Lu Z, Liu N, Huang H, et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol. 2023. PMID: 37261455
- Sundgren NC, Giraud GD, Schultz JM, et al. Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes. Am J Physiol Regul Integr Comp Physiol. 2003. PMID: 12947030
- Levolger S, Wiemer EAC, van Vugt JLA, et al. Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting. Sci Rep. 2019. PMID: 31285507
- Engel MG, Narayan S, Cui MH, et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. J Alzheimers Dis. 2024. PMID: 39610283
- Mukama T, Srour B, Johnson T, Katzke V, Kaaks R. IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg. J Clin Endocrinol Metab. 2023. PMID: 37066827
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GHRH analog (GRF 1-29)
Sermorelin protocol guide: pharmacology, dosing, IGF-1 monitoring, and the non-responder reality
The only GHRH analog still Category 1 compoundable. Daily injection, 6 to 12 month protocol, 30 to 40 percent non-responder rate, and IGF-1 the biomarker that decides the answer.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
Oral GH secretagogue (MK-677)
Ibutamoren (MK-677) guide: oral ghrelin receptor agonist, water retention, glucose elevation, WADA prohibition
The only oral GH secretagogue. Real GH and IGF-1 elevation. Real water retention. Real fasting-glucose drift. WADA prohibited. Monitoring is mandatory.
Continue reading